logo

Last Update

This profile was last updated on 5/2/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Randi Cohen?

Randi J. Cohen

Doctor

University of Maryland Medical Center

HQ Phone:  (410) 328-9600

Direct Phone: (410) ***-****direct phone

Email: r***@***.edu

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

University of Maryland Medical Center

22 South Green St Room P1H10

Baltimore, Maryland,21201

United States

Company Description

The University of Maryland Medical System's Maryland Brain Attack Center was created to provide the most advanced and innovative treatments to stroke patients throughout the state of Maryland. The Center utilizes a multidisciplinary team of health care profess...more

Background Information

Employment History

Physician In the Department of Radiation Oncology

Stewart Greenebaum Cancer Center


Associate Director of Clinical Research, Community Practice Program

University of Maryland Baltimore Washington Medical Center


Institutional Principal Investigator

University of Maryland


Web References(6 Total References)


www.news-medical.net

"Overall survival and breast cancer-specific survival were significantly better at all time points for elderly women with Stage I, estrogen-receptor (ER)-positive breast cancer with no lymph node involvement who received radiation therapy following surgery to remove the tumor," says lead author Randi J. Cohen, M.D., M.S., an assistant professor of radiation oncology at the University of Maryland School of Medicine and a physician in the Department of Radiation Oncology at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.
"Our findings suggest that adjuvant radiation therapy should be strongly considered as part of the treatment regimen for otherwise healthy elderly women with early ER-positive breast cancer," Dr. Cohen says.


mapinfo.syssrc.com

"Overall survival and breast cancer-specific survival were significantly better at all time points for elderly women with Stage I, estrogen-receptor (ER)-positive breast cancer with no lymph node involvement who received radiation therapy following surgery to remove the tumor," says lead author Randi J. Cohen, M.D., M.S., an assistant professor of radiation oncology at the University of Maryland School of Medicine and a physician in the Department of Radiation Oncology at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.
"Our findings suggest that adjuvant radiation therapy should be strongly considered as part of the treatment regimen for otherwise healthy elderly women with early ER-positive breast cancer," Dr. Cohen says.


chesphysician.com [cached]

Illustrating that point is Randi Cohen, MD, MS, associate director of clinical research, Community Practice Program, University of Maryland Baltimore Washington Medical Center (BWMC).
She notes, "We've been selective about which trials go to the community. Dr. Cohen noted that Dr. Hongchao Pan's retrospective study of 80,000 women, presented at this year's American Society of Clinical Oncology meeting, found that obese women under age 50 with estrogen receptor-positive breast cancer have a 34% greater risk of death than those who were not obese. Overweight women were also at higher risk than those of normal weight. However, the risk in menopausal women did not increase with increased weight. "The message for physicians is that this is one more reason to encourage their patients to be proactive about diet and exercise. However, Phase III randomized trials are the gold standard," Dr. Cohen reminds clinicians. Metastatic Breast Cancer Trial Dr. Cohen is the University of Maryland institutional principal investigator for E2108, a randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients With Metastatic Breast Cancer. The goal of this prospective, randomized trial of 368 women is to determine if early, localized therapy to the breast can improve quality of life and/or prolong survival for patients with Stage IV breast cancer. One group will receive the current standard of care, consisting of chemotherapy, hormone therapy or other medications. The second group will receive the standard treatment plus surgery (either lumpectomy or mastectomy) and possibly also radiation therapy to the breast. Dr. Cohen explains, "Some clinicians think that primary breast tumor treatment is not important once the cancer has metastasized, but others think treatment of the breast will improve patient outcomes. All patients in this study will get systemic chemotherapy or hormone therapy up front, then those who do well will be randomly assigned to one of the groups. "Good retrospective data suggests there is benefit to treating the breast in select women with metastatic breast cancer," she continues, "and my guess is that for women with minimal comorbidities who can perform their normal activities, treating the primary cancer site will help them. But women have to deal with so much emotional duress and costs that we don't want to add to their burden unnecessarily." Prostate Cancer Clinical Trials Dr. Cohen is also involved in two randomized Phase III clinical trials for prostate cancer. The first is RTOG 0815, a Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer. The goal of this trial is to determine if those with intermediate risk, clinically localized prostate adenocarcinoma (Gleason Score of 7 and/or PSA between 10 and 20) benefit from adding six months of androgen deprivation therapy (ADT) to their radiation therapy regimen. The second prostate trial, RTOG 0924, evaluates whether ADT combined with whole-pelvic radiation therapy improves survival in patients with unfavorable intermediate-risk or favorable high-risk prostate cancer better than ADT plus radiation therapy to only the prostate and seminal vesicles. "Thanks to clinical trials, there have been significant improvements in radiation therapy techniques, delivery and planning in the past 10 years," Dr. Cohen reflects. Randi Cohen, MD, MS,assistant professor, University of Maryland and associate director of Clinical Research, Community Practice Program, University of Maryland Baltimore Washington Medical Center


www.umgcc.org [cached]

Randi J. Cohen, M.D., M.S.
Randi J. Cohen, M.D., M.S. Assistant Professor of Radiation Oncology Special Interests: Breast Cancer, Prostate Cancer and Prostate Brachytherapy, Lung Cancer, Stereotactic Body Radiation Therapy (SBRT)


appliedradiationoncology.com

D. Hunter Boggs, MD, Steven Feigenberg, MD, and Randi Cohen, MD
Prepared by D. Hunter Boggs, MD, Steven Feigenberg, MD, and Randi Cohen, MD, while at University of Maryland School of Medicine, Baltimore, MA. Prepared by D. Hunter Boggs, MD, Steven Feigenberg, MD, and Randi Cohen, MD, while at University of Maryland School of Medicine, Baltimore, MA. Prepared by D. Hunter Boggs, MD, Steven Feigenberg, MD, and Randi Cohen, MD, while at University of Maryland School of Medicine, Baltimore, MA.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory